Related Experiment Video
Updated: Nov 17, 2025

Mucin Agarose Gel Electrophoresis: Western Blotting for High-molecular-weight Glycoproteins
Published on: June 14, 2016
Overexpression of Substance P in pig airways increases MUC5AC through an NF-kβ pathway
Mariana Sponchiado1, Yan-Shin Liao1, Kalina R Atanasova1,2
1Department of Physiological Sciences, University of Florida, Gainesville, FL, USA.
Abstract:
Substance P (SP) is a tachykinin that regulates airway mucous secretion in both health and disease. Our study aimed to determine whether overexpression of SP without pre-existing inflammation was sufficient to induce changes in mucin secretion and transport in small airways. Utilizing porcine precision-cut lung slices, we measured the impact of AAV-mediated overexpression of SP on airway physiology ex vivo. Immunofluorescence signal intensity for MUC5AC was significantly increased in SP-overexpressed precision-cut lung slices compared to GFP controls. No difference in MUC5B signal intensity between treatments was detected. SP-overexpressed precision-cut lung slices also exhibited decreased IL10 mRNA, an important inhibitor of mucous cell metaplasia. Overt deficits in mucociliary transport were not noted, though a trend for decreased mean transport speed was detected in methacholine-challenged airways overexpressing SP compared to GFP controls. Pharmacologic inhibition of the NF-kβ pathway abrogated the effects of overexpression of SP on both MUC5AC and IL10. Collectively, these data suggest that overexpression of SP in the absence of existing inflammation increases MUC5AC via activation of the NF-kβ pathway. Thus, these data further highlight SP as a key driver of abnormal mucous secretion and underscore NF-kβ signaling as a pathway of potential therapeutic intervention.
Insights
Overexpression of Substance P (SP) increases MUC5AC, a key mucin, in airways by activating the NF-κβ pathway. This occurs even without inflammation, highlighting SP
Area of Science:
- Pulmonary Medicine
- Cellular Biology
- Molecular Signaling
Background:
- Substance P (SP) is a neuropeptide regulating airway mucus secretion.
- Its role in initiating mucus changes without inflammation is unclear.
- Mucin overproduction contributes to airway obstruction.
Purpose of the Study:
- To investigate if Substance P overexpression alone induces airway mucus changes.
- To elucidate the signaling pathways involved in SP-mediated mucus secretion.
- To assess the impact on mucociliary transport.
Main Methods:
- Porcine precision-cut lung slices (PCLS) were used for ex vivo studies.
- Adeno-associated virus (AAV) mediated SP overexpression.
- Immunofluorescence for MUC5AC and MUC5B, IL10 mRNA levels, and mucociliary transport were measured.
- NF-κβ pathway inhibition was employed.
Main Results:
- SP overexpression significantly increased MUC5AC levels but not MUC5B.
- IL10 mRNA expression was decreased in SP-overexpressing PCLS.
- A trend for reduced mucociliary transport speed was observed under methacholine challenge.
- NF-κβ pathway inhibition abolished SP-induced MUC5AC and IL10 changes.
Conclusions:
- Substance P overexpression, independent of inflammation, drives MUC5AC increase via NF-κβ activation.
- SP is a significant factor in abnormal airway mucus secretion.
- NF-κβ signaling represents a potential therapeutic target for mucus-related airway diseases.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Nitric Oxide Signaling Pathway
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

